RT Journal Article
SR Electronic
T1 Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 496190
DO 10.1101/496190
A1 Chen, Wei
A1 Kang, Tao
A1 Yuan, Rongliang
A1 Zhang, Yuyang
A1 Xin, Siqi
A1 Shao, Congwen
A1 Jing, Shenrong
YR 2018
UL http://biorxiv.org/content/early/2018/12/13/496190.abstract
AB Noroviruses (NoVs) are a major cause of acute viral gastroenteritis in adults and children worldwide. Lacking of cell culture system and animals models that must be considered the virus like particles (VLPs) used as an effective vaccine development. In the present study, we investigated the expression of the major capsid protein (VP1) of Genogroup II, genotype 17 (GII.17) NoV using recombinant baculovirus system in insect cells and saliva binding blockade assay to detect their protective potency. Our results showed that GII.17 VLPs could be successfully generated in sf9 insect cells and electron microscopic revealed that GII.17 VLPs was visualized as spherical particles of −35nm in diameter. Immunized mouse with purified VLPs produced GII.17 specific sera and could efficiently block GII.17 VLPs binding to saliva histo-blood group antigens (HBGAs). Together, these results suggested that GII.17 VLPs represent a promising vaccine candidate against NoV GII.17 infection and strongly support further preclinical and clinical studies.